BRAF and Lynch syndrome: People with BRAF mutation and microsatellite instability-high (MSI-H) tumours had a better overall prognosis than people with BRAF mutation and microsatellite stable (MSS) illness, and it turns out, using MSI to screen for Lynch syndrome and identify patients who could benefit from immunotherapy is becoming increasingly important in CRC [10].